Additionally, research indicates upregulation of growth hormone receptor expression in tendon-derived fibroblasts, potentially amplifying growth hormonemediated proliferative responses during repair
What the research shows In the SURMOUNT-1 trial, adults taking once-weekly tirzepatide lost an average of about 15% to 21% of their body weight over 72 weeks depending on dose
Patients should feel confident and supported in their ability to manage weight and health without relying solely on medication
For most patients, GLP-1 drugs (semaglutide and tirzepatide) generally offer the most favourable combination of weight loss and tolerability among approved options
She receives fees to give lectures by Novo Nordisk, Lilly, Novartis, AstraZeneca, Medtronic, Biomm, Sanofi, Abbott, and Roche